EPISODE · Mar 26, 2024 · 16 MIN
Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?
from Keeping Current CME
Do you know how to interpret the results of recent phase 3 clinical trials in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? Credit available for this activity expires: 3/22/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000444?ecd=bdc_podcast_libsyn_mscpedu
Embed this episode
NOW PLAYING
Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?
0:00
16:18
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 16 minutes long.
When was this Keeping Current CME episode published?
This episode was published on March 26, 2024.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!